{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:23:22Z","timestamp":1792790602437,"version":"4.5.0"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2020,12,14]],"date-time":"2020-12-14T00:00:00Z","timestamp":1607904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,12,14]],"date-time":"2020-12-14T00:00:00Z","timestamp":1607904000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["T32-AI060573"],"award-info":[{"award-number":["T32-AI060573"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"},{"id":"https:\/\/ror.org\/033jnv181","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["T32-CA9161"],"award-info":[{"award-number":["T32-CA9161"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"},{"id":"https:\/\/ror.org\/033jnv181","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["T32-AI060573"],"award-info":[{"award-number":["T32-AI060573"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"},{"id":"https:\/\/ror.org\/033jnv181","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["R01-CA158383"],"award-info":[{"award-number":["R01-CA158383"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"},{"id":"https:\/\/ror.org\/033jnv181","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["P30-CA062203"],"award-info":[{"award-number":["P30-CA062203"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"},{"id":"https:\/\/ror.org\/033jnv181","id-type":"ROR","asserted-by":"crossref"}]},{"name":"U.S. Department of Health & Human Services | National Institutes of Health","id":[{"id":"https:\/\/ror.org\/033jnv181","id-type":"ROR","asserted-by":"crossref"}]},{"name":"U.S. Department of Health & Human Services | National Institutes of Health","id":[{"id":"https:\/\/ror.org\/033jnv181","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/100006955","name":"U.S. Department of Health & Human Services | NIH | Office of Extramural Research, National Institutes of Health","doi-asserted-by":"publisher","award":["CA178509"],"award-info":[{"award-number":["CA178509"]}],"id":[{"id":"10.13039\/100006955","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Breast Cancer Research Fund BCRF-16-143","id":[{"id":"https:\/\/ror.org\/03xzf6x18","id-type":"ROR","asserted-by":"crossref"}]},{"name":"U.S. Department of Health & Human Services | National Institutes of Health","id":[{"id":"https:\/\/ror.org\/033jnv181","id-type":"ROR","asserted-by":"crossref"}]},{"name":"U.S. Department of Health & Human Services | National Institutes of Health","id":[{"id":"https:\/\/ror.org\/033jnv181","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2021,3,16]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The BCL2 inhibitor venetoclax has shown efficacy in several hematologic malignancies, with the greatest response rates in indolent blood cancers such as chronic lymphocytic leukaemia. There is a lower response rate to venetoclax monotherapy in diffuse large B-cell lymphoma (DLBCL).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We tested inhibitors of cap-dependent mRNA translation for the ability to sensitise DLBCL and mantle cell lymphoma (MCL)\u00a0cells to apoptosis by venetoclax. We compared the mTOR kinase inhibitor (TOR-KI) MLN0128 with SBI-756, a compound targeting eukaryotic translation initiation factor 4G1 (eIF4G1), a scaffolding protein in the eIF4F complex.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Treatment of DLBCL and MCL\u00a0cells with SBI-756 synergised with venetoclax to induce apoptosis in vitro, and enhanced venetoclax efficacy in vivo. SBI-756 prevented eIF4E-eIF4G1 association and cap-dependent translation without affecting mTOR substrate phosphorylation. In TOR-KI-resistant DLBCL cells lacking eIF4E binding protein-1, SBI-756 still sensitised to venetoclax. SBI-756 selectively reduced translation of mRNAs encoding ribosomal proteins and translation factors, leading to a reduction in protein synthesis rates in sensitive cells. When normal lymphocytes were treated with SBI-756, only B cells had reduced viability, and this correlated with reduced protein synthesis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our data highlight a novel combination for treatment of aggressive lymphomas, and establishes its efficacy and selectivity using preclinical models.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1038\/s41416-020-01205-9","type":"journal-article","created":{"date-parts":[[2020,12,14]],"date-time":"2020-12-14T06:13:36Z","timestamp":1607926416000},"page":"1098-1109","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Targeting eIF4F translation initiation complex with SBI-756 sensitises B lymphoma cells to venetoclax"],"prefix":"10.1038","volume":"124","author":[{"given":"Lee-or","family":"Herzog","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beth","family":"Walters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Buono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Scott","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharmila","family":"Mallya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amos","family":"Fung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Honyin","family":"Chiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boyang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony B.","family":"Pinkerton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R.","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3859-0400","authenticated-orcid":false,"given":"Ze\u2019ev A.","family":"Ronai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1796-5162","authenticated-orcid":false,"given":"David A.","family":"Fruman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,12,14]]},"reference":[{"key":"1205_CR1","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.cell.2017.02.004","volume":"168","author":"RA Saxton","year":"2017","unstructured":"Saxton, R. A. & Sabatini, D. M. mTOR signaling in growth, metabolism, and disease. Cell 168, 960\u2013976 (2017).","journal-title":"Cell"},{"key":"1205_CR2","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.cell.2017.09.027","volume":"171","author":"A Reddy","year":"2017","unstructured":"Reddy, A., Zhang, J., Davis, N. S., Moffitt, A. B., Love, C. L., Waldrop, A. et al. Genetic and functional drivers of diffuse large b cell lymphoma. Cell 171, 481\u2013494.e15 (2017).","journal-title":"Cell"},{"key":"1205_CR3","doi-asserted-by":"crossref","first-page":"e59335","DOI":"10.1371\/journal.pone.0059335","volume":"8","author":"K Nemes","year":"2013","unstructured":"Nemes, K., Sebesty\u00e9n, A., M\u00e1rk, A., Hajdu, M., Kenessey, I., Sticz, T. et al. Mammalian target of rapamycin (mTOR) activity dependent phospho-protein expression in childhood acute lymphoblastic leukemia (ALL). PLoS ONE 8, e59335 (2013).","journal-title":"PLoS ONE"},{"key":"1205_CR4","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrd4505","volume":"14","author":"M Bhat","year":"2015","unstructured":"Bhat, M., Robichaud, N., Hulea, L., Sonenberg, N., Pelletier, J. & Topisirovic, I. Targeting the translation machinery in cancer. Nat. Rev. Drug Discov. 14, 261\u2013278 (2015).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1205_CR5","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1158\/0008-5472.CAN-14-2789","volume":"75","author":"J Pelletier","year":"2005","unstructured":"Pelletier, J., Graff, J., Ruggero, D. & Sonenberg, N. Targeting the eIF4F translation initiation complex: a critical nexus for cancer development. Cancer Res. 75, 250\u2013263 (2005).","journal-title":"Cancer Res."},{"key":"1205_CR6","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1158\/1078-0432.CCR-14-2362","volume":"23","author":"H Malka-Mahieu","year":"2017","unstructured":"Malka-Mahieu, H., Newman, M., D\u00e9saubry, L., Robert, C. & Vagner, S. Molecular pathways: the eIF4F translation initiation complex-new opportunities for cancer treatment. Clin. Cancer Res. 23, 21\u201325 (2017).","journal-title":"Clin. Cancer Res."},{"key":"1205_CR7","doi-asserted-by":"crossref","first-page":"14632","DOI":"10.18632\/oncotarget.4104","volume":"6","author":"AY Shull","year":"2015","unstructured":"Shull, A. Y., Noonepalle, S. K., Awan, F. T., Liu, J., Pei, L., Bollag, R. J. et al. RPPA-based protein profiling reveals eIF4G overexpression and 4E-BP1 serine 65 phosphorylation as molecular events that correspond with a pro-survival phenotype in chronic lymphocytic leukemia. Oncotarget 6, 14632\u201314645 (2015).","journal-title":"Oncotarget"},{"key":"1205_CR8","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/nm.2091","volume":"16","author":"MR Janes","year":"2010","unstructured":"Janes, M. R., Limon, J. J., So, L., Chen, J., Lim, R. J., Chavez, M. A. et al. Effective and selective targeting of leukemia cells using a TORC1\/2 kinase inhibitor. Nat. Med. 16, 205\u2013213 (2010).","journal-title":"Nat. Med."},{"key":"1205_CR9","doi-asserted-by":"crossref","first-page":"2711","DOI":"10.1182\/blood-2015-02-629485","volume":"127","author":"S Yun","year":"2016","unstructured":"Yun, S., Vincelette, N. D., Knorr, K. L. B., Almada, L. L., Schneider, P. A., Peterson, K. L. et al. 4EBP1\/c-MYC\/PUMA and NF-\u03baB\/EGR1\/BIM pathways underlie cytotoxicity of mTOR dual inhibitors in malignant lymphoid cells. Blood 127, 2711\u20132722 (2016).","journal-title":"Blood"},{"key":"1205_CR10","doi-asserted-by":"crossref","first-page":"17414","DOI":"10.1073\/pnas.0809136105","volume":"105","author":"AY Choo","year":"2008","unstructured":"Choo, A. Y., Yoon, S.-O., Kim, S. G., Roux, P. P. & Blenis, J. Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation. Proc. Natl Acad. Sci. USA 105, 17414\u201317419 (2008).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1205_CR11","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1111\/bcp.12888","volume":"82","author":"J-HS Lee","year":"2016","unstructured":"Lee, J.-H. S., Vo, T.-T. & Fruman, D. A. Targeting mTOR for the treatment of B cell malignancies. Br. J. Clin. Pharmacol. 82, 1213\u20131228 (2016).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"1205_CR12","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1038\/nrd3531","volume":"10","author":"D Benjamin","year":"2011","unstructured":"Benjamin, D., Colombi, M., Moroni, C. & Hall, M. N. Rapamycin passes the torch: a new generation of mTOR inhibitors. Nat. Rev. Drug Discov. 10, 868\u2013880 (2011).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1205_CR13","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1038\/leu.2012.276","volume":"27","author":"MR Janes","year":"2016","unstructured":"Janes, M. R., Vu, C., Mallya, S., Shieh, M. P., Limon, J. J., Li, L. S. et al. Efficacy of the investigational mTOR kinase inhibitor MLN0128\/INK128 in models of B-cell acute lymphoblastic leukemia. Leukemia 27, 586\u2013594 (2016).","journal-title":"Leukemia"},{"key":"1205_CR14","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s00280-017-3343-4","volume":"80","author":"HA Burris","year":"2017","unstructured":"Burris, H. A., Kurkjian, C. D., Hart, L., Pant, S., Murphy, P. B., Jones, S. F. et al. TAK-228 (formerly MLN0128), an investigational dual TORC1\/2 inhibitor plus paclitaxel, with\/without trastuzumab, in patients with advanced solid malignancies. Cancer Chemother. Pharmacol. 80, 261\u2013273 (2017).","journal-title":"Cancer Chemother. Pharmacol."},{"key":"1205_CR15","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1158\/2159-8290.CD-11-0085","volume":"1","author":"VS Rodrik-Outmezguine","year":"2011","unstructured":"Rodrik-Outmezguine, V. S., Chandarlapaty, S., Pagano, N. C., Poulikakos, P. I., Scaltriti, M., Moskatel, E. et al. mTOR kinase inhibition causes feedback-dependent biphasic regulation of AKT signaling. Cancer Discov. 1, 248\u2013259 (2011).","journal-title":"Cancer Discov."},{"key":"1205_CR16","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1158\/2159-8290.CD-13-0929","volume":"4","author":"BC Grabiner","year":"2014","unstructured":"Grabiner, B. C., Nardi, V., Birsoy, K., Possemato, R., Shen, K., Sinha, S. et al. A diverse array of cancer-associated MTOR mutations are hyperactivating and can predict rapamycin sensitivity. Cancer Discov. 4, 554\u2013563 (2014).","journal-title":"Cancer Discov."},{"key":"1205_CR17","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.cell.2015.05.049","volume":"162","author":"ML Truitt","year":"2015","unstructured":"Truitt, M. L., Conn, C. S., Shi, Z., Pang, X., Tokuyasu, T., Coady, A. M. et al. Differential requirements for eIF4E dose in normal development and cancer. Cell 162, 59\u201371 (2015).","journal-title":"Cell"},{"key":"1205_CR18","doi-asserted-by":"crossref","first-page":"10853","DOI":"10.1073\/pnas.0804821105","volume":"105","author":"JR Mills","year":"2008","unstructured":"Mills, J. R., Hippo, Y., Robert, F., Chen, S. M. H., Malina, A., Lin, C.-J. et al. mTORC1 promotes survival through translational control of Mcl-1. Proc. Natl Acad. Sci. USA 105, 10853\u201310858 (2008).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1205_CR19","doi-asserted-by":"crossref","first-page":"5211","DOI":"10.1158\/0008-5472.CAN-15-0885","volume":"75","author":"Y Feng","year":"2015","unstructured":"Feng, Y., Pinkerton, A. B., Hulea, L., Zhang, T., Davies, M. A., Grotegut, S. et al. SBI-0640756 attenuates the growth of clinically unresponsive melanomas by disrupting the eIF4F translation initiation complex. Cancer Res. 75, 5211\u20135218 (2015).","journal-title":"Cancer Res."},{"key":"1205_CR20","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/j.ccell.2018.11.004","volume":"34","author":"D Merino","year":"2018","unstructured":"Merino, D., Kelly, G. L., Lessene, G., Wei, A. H., Roberts, A. W. & Strasser, A. BH3-mimetic drugs: blazing the trail for new cancer medicines. Cancer Cell 34, 879\u2013891 (2018).","journal-title":"Cancer Cell"},{"key":"1205_CR21","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1158\/2159-8290.CD-17-0797","volume":"7","author":"JD Leverson","year":"2017","unstructured":"Leverson, J. D., Sampath, D., Souers, A. J., Rosenberg, S. H., Fairbrother, W. J., Amiot, M. et al. Found in translation: how preclinical research is guiding the clinical development of the BCL2-selective inhibitor venetoclax. Cancer Discov. 7, 1376\u20131393 (2017).","journal-title":"Cancer Discov."},{"key":"1205_CR22","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1513257","volume":"374","author":"AW Roberts","year":"2016","unstructured":"Roberts, A. W., Davids, M. S., Pagel, J. M., Kahl, B. S., Puvvada, S. D., Gerecitano, J. F. et al. Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia. N. Engl. J. Med. 374, 311\u2013322 (2016).","journal-title":"N. Engl. J. Med."},{"key":"1205_CR23","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1056\/NEJMoa1713976","volume":"378","author":"JF Seymour","year":"2018","unstructured":"Seymour, J. F., Kipps, T. J., Eichhorst, B., Hillmen, P., D\u2019Rozario, J., Assouline, S. et al. Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia. N. Engl. J. Med. 378, 1107\u20131120 (2018).","journal-title":"N. Engl. J. Med."},{"key":"1205_CR24","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","volume":"133","author":"CD DiNardo","year":"2019","unstructured":"DiNardo, C. D., Pratz, K., Pullarkat, V., Jonas, B. A., Arellano, M., Becker, P. S. et al. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood 133, 7\u201317 (2019).","journal-title":"Blood"},{"key":"1205_CR25","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1200\/JCO.2016.70.4320","volume":"35","author":"MS Davids","year":"2017","unstructured":"Davids, M. S., Roberts, A. W., Seymour, J. F., Pagel, J. M., Kahl, B. S., Wierda, W. G. et al. Phase I first-in-human study of venetoclax in patients with relapsed or refractory non-hodgkin lymphoma. J. Clin. Oncol. 35, 826\u2013833 (2017).","journal-title":"J. Clin. Oncol."},{"key":"1205_CR26","doi-asserted-by":"crossref","first-page":"579","DOI":"10.4049\/jimmunol.1800602","volume":"202","author":"H Chiu","year":"2019","unstructured":"Chiu, H., Jackson, L. V., Oh, K. I., Mai, A., Ronai, Z. A., Ruggero, D. et al. The mTORC1\/4E-BP\/eIF4E axis promotes antibody class switching in B lymphocytes. J. Immunol. 202, 579\u2013590 (2019).","journal-title":"J. Immunol."},{"key":"1205_CR27","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/nature13572","volume":"513","author":"L Boussemart","year":"2014","unstructured":"Boussemart, L., Malka-Mahieu, H., Girault, I., Allard, D., Hemmingsson, O., Tomasic, G. et al. eIF4F is a nexus of resistance to anti-BRAF and anti-MEK cancer therapies. Nature 513, 105\u2013109 (2014).","journal-title":"Nature"},{"key":"1205_CR28","doi-asserted-by":"crossref","DOI":"10.1186\/s12864-018-5166-z","volume":"19","author":"AW Ernlund","year":"2018","unstructured":"Ernlund, A. W., Schneider, R. J. & Ruggles, K. V. RIVET: comprehensive graphic user interface for analysis and exploration of genome-wide translatomics data. BMC Genomics 19, 809 (2018).","journal-title":"BMC Genomics"},{"key":"1205_CR29","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2014.525","volume":"6","author":"GS Choudhary","year":"2015","unstructured":"Choudhary, G. S., Al-Harbi, S., Mazumder, S., Hill, B. T., Smith, M. R., Bodo, J. et al. MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K\/AKT\/mTOR activation in lymphoid malignancies. Cell Death Dis. 6, e1593 (2015).","journal-title":"Cell Death Dis."},{"key":"1205_CR30","first-page":"ra57","volume":"9","author":"L So","year":"2016","unstructured":"So, L., Lee, J., Palafox, M., Mallya, S., Woxland, C. G., Arguello, M. et al. The 4E-BP-eIF4E axis promotes rapamycin-sensitive growth and proliferation in lymphocytes. Sci. Signal. 9, ra57 (2016).","journal-title":"Sci. Signal."},{"key":"1205_CR31","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","volume":"70","author":"T-C Chou","year":"2010","unstructured":"Chou, T.-C. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 70, 440\u2013446 (2010).","journal-title":"Cancer Res."},{"key":"1205_CR32","doi-asserted-by":"crossref","first-page":"e88865","DOI":"10.1371\/journal.pone.0088865","volume":"9","author":"S Mallya","year":"2014","unstructured":"Mallya, S., Fitch, B. A., Lee, J. S., So, L., Janes, M. R. & Fruman, D. A. Resistance to mTOR kinase inhibitors in lymphoma cells lacking 4EBP1. PLoS ONE 9, e88865 (2014).","journal-title":"PLoS ONE"},{"key":"1205_CR33","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1038\/onc.2013.100","volume":"33","author":"Y Martineau","year":"2013","unstructured":"Martineau, Y., Azar, R., M\u00fcller, D., Lasfargues, C., El Khawand, S., Anesia, R. et al. Pancreatic tumours escape from translational control through 4E-BP1 loss. Oncogene 33, 1367\u20131374 (2013).","journal-title":"Oncogene"},{"key":"1205_CR34","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1002\/(SICI)1097-0142(19970615)79:12<2385::AID-CNCR13>3.0.CO;2-N","volume":"79","author":"BD Li","year":"1997","unstructured":"Li, B. D., Liu, L., Dawson, M. & De Benedetti, A. Overexpression of eukaryotic initiation factor 4E (eIF4E) in breast carcinoma. Cancer 79, 2385\u20132390 (1997).","journal-title":"Cancer"},{"key":"1205_CR35","first-page":"815","volume":"9","author":"T Xu","year":"2016","unstructured":"Xu, T., Zong, Y., Peng, L., Kong, S., Zhou, M., Zou, J. et al. Overexpression of eIF4E in colorectal cancer patients is associated with liver metastasis. Onco Targets Ther. 9, 815\u2013822 (2016).","journal-title":"Onco Targets Ther."},{"key":"1205_CR36","doi-asserted-by":"crossref","first-page":"6468","DOI":"10.1158\/0008-5472.CAN-12-2395","volume":"72","author":"T Alain","year":"2012","unstructured":"Alain, T., Morita, M., Fonseca, B. D., Yanagiya, A., Siddiqui, N., Bhat, M. et al. eIF4E\/4E-BP ratio predicts the efficacy of mTOR targeted therapies. Cancer Res. 72, 6468\u20136476 (2012).","journal-title":"Cancer Res."},{"key":"1205_CR37","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1101\/gr.197566.115","volume":"26","author":"V Gandin","year":"2016","unstructured":"Gandin, V., Masvidal, L., Hulea, L., Gravel, S.-P., Cargnello, M., McLaughlan, S. et al. nanoCAGE reveals 5\u2019 UTR features that define specific modes of translation of functionally related MTOR-sensitive mRNAs. Genome Res. 26, 636\u2013648 (2016).","journal-title":"Genome Res."},{"key":"1205_CR38","doi-asserted-by":"crossref","first-page":"eaaq1240","DOI":"10.1126\/scitranslmed.aaq1240","volume":"10","author":"JS Lee","year":"2018","unstructured":"Lee, J. S., Roberts, A., Juarez, D., Vo T.-T. T., Bhatt, S., Herzog, L. et al. Statins enhance efficacy of venetoclax in blood cancers. Sci. Transl. Med. 10, eaaq1240 (2018).","journal-title":"Sci. Transl. Med"},{"key":"1205_CR39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/10428194.2017.1283032","volume":"58","author":"P Bose","year":"2017","unstructured":"Bose, P., Gandhi, V. & Konopleva, M. Pathways and mechanisms of venetoclax resistance. Leuk. Lymphoma 58, 1\u201317 (2017).","journal-title":"Leuk. Lymphoma"},{"key":"1205_CR40","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1182\/blood-2018-11-880526","volume":"33","author":"AD Zelenetz","year":"2019","unstructured":"Zelenetz, A. D., Salles, G., Mason, K. D., Casulo, C., Le Gouill, S., Sehn, L. H. et al. Venetoclax plus R- or G-CHOP in non-Hodgkin lymphoma: results from the CAVALLI phase 1b trial. Blood 33, 1964\u20131976 (2019).","journal-title":"Blood"},{"key":"1205_CR41","doi-asserted-by":"crossref","unstructured":"de Jong, M. R. W., Langendonk, M., Reitsma, B., Nijland, M., van den Berg, A., Ammatuna, E. et al. Heterogeneous pattern of dependence on anti-apoptotic BCL-2 family proteins upon CHOP treatment in diffuse large B-cell lymphoma. Int. J. Mol. Sci. 20, 6036 (2019).","DOI":"10.3390\/ijms20236036"},{"key":"1205_CR42","doi-asserted-by":"crossref","unstructured":"Zhang, X., Bi, C., Lu, T., Zhang, W., Yue, T., Wang, C. et al. Targeting translation initiation by synthetic rocaglates for treating MYC-driven lymphomas. Leukemia 34, 138\u2013150 (2019).","DOI":"10.1038\/s41375-019-0503-z"},{"key":"1205_CR43","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1080\/10428190802428369","volume":"49","author":"J Houldsworth","year":"2008","unstructured":"Houldsworth, J., Petlakh, M., Olshen, A. B. & Chaganti, R. S. K. Pathway activation in large B-cell non-Hodgkin lymphoma cell lines by doxorubicin reveals prognostic markers of in vivo response. Leuk. Lymphoma 49, 2170\u20132180 (2008).","journal-title":"Leuk. Lymphoma"},{"key":"1205_CR44","doi-asserted-by":"crossref","first-page":"3212","DOI":"10.1158\/1078-0432.CCR-12-2185","volume":"19","author":"S Willimott","year":"2013","unstructured":"Willimott, S., Beck, D., Ahearne, M. J., Adams, V. C. & Wagner, S. D. Cap-translation inhibitor, 4EGI-1, restores sensitivity to ABT-737 apoptosis through cap-dependent and -independent mechanisms in chronic lymphocytic leukemia. Clin. Cancer Res. 19, 3212\u20133223 (2013).","journal-title":"Clin. Cancer Res."},{"key":"1205_CR45","unstructured":"Huang, S., Jiang, C., Guo, H., Wang, J., Liu, Y., Li, C. et al. Resistance mechanisms underlying venetoclax resistance in mantle cell lymphoma. Blood 130, (Supplement 1):2749 (2017)."},{"key":"1205_CR46","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ccr.2012.05.019","volume":"22","author":"MJ Bywater","year":"2012","unstructured":"Bywater, M. J., Poortinga, G., Sanij, E., Hein, N., Peck, A., Cullinane, C. et al. Inhibition of RNA polymerase I as a therapeutic strategy to promote cancer-specific activation of p53. Cancer Cell. 22, 51\u201365 (2012).","journal-title":"Cancer Cell."},{"key":"1205_CR47","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1158\/2159-8290.CD-14-0673","volume":"6","author":"JR Devlin","year":"2016","unstructured":"Devlin, J. R., Hannan, K. M., Hein, N., Cullinane, C., Kusnadi, E., Ng, P. Y. et al. Combination therapy targeting ribosome biogenesis and mRNA translation synergistically extends survival in MYC-driven lymphoma. Cancer Discov. 6, 59\u201370 (2016).","journal-title":"Cancer Discov."},{"key":"1205_CR48","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.cell.2006.11.046","volume":"128","author":"NJ Moerke","year":"2017","unstructured":"Moerke, N. J., Aktas, H., Chen, H., Cantel, S., Reibarkh, M. Y., Fahmy, A. et al. Small-molecule inhibition of the interaction between the translation initiation factors eIF4E and eIF4G. Cell 128, 257\u2013267 (2017).","journal-title":"Cell"},{"key":"1205_CR49","doi-asserted-by":"crossref","first-page":"E2298","DOI":"10.1073\/pnas.1301838110","volume":"110","author":"S Lim","year":"2013","unstructured":"Lim, S., Saw, T. Y., Zhang, M., Janes, M. R., Nacro, K., Hill, J. et al. Targeting of the MNK-eIF4E axis in blast crisis chronic myeloid leukemia inhibits leukemia stem cell function. Proc. Natl Acad. Sci. USA 110, E2298\u2013E2307 (2013).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1205_CR50","doi-asserted-by":"crossref","first-page":"3516","DOI":"10.1021\/acs.jmedchem.7b01795","volume":"61","author":"SH Reich","year":"2018","unstructured":"Reich, S. H., Sprengeler, P. A., Chiang, G. G., Appleman, J. R., Chen, J., Clarine, J. et al. Structure-based design of pyridone-aminal eFT508 targeting dysregulated translation by selective mitogen-activated protein kinase interacting kinases 1 and 2 (MNK1\/2) inhibition. J. Med. Chem. 61, 3516\u20133540 (2018).","journal-title":"J. Med. Chem."},{"key":"1205_CR51","first-page":"2651","volume":"118","author":"M-E Bordeleau","year":"2008","unstructured":"Bordeleau, M.-E., Robert, F., Gerard, B., Lindqvist, L., Chen, S. M. H., Wendel, H.-G. et al. Therapeutic suppression of translation initiation modulates chemosensitivity in a mouse lymphoma model. J. Clin. Invest. 118, 2651\u20132660 (2008).","journal-title":"J. Clin. Invest"},{"key":"1205_CR52","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1016\/j.chembiol.2019.08.008","volume":"26","author":"J Chu","year":"2019","unstructured":"Chu, J., Zhang, W., Cencic, R., Devine, W. G., Beglov, D., Henkel, T. et al. Amidino-rocaglates: a potent class of eIF4A inhibitors. Cell Chem. Biol. 26, 1586\u20131593.e3 (2019).","journal-title":"Cell Chem. Biol."},{"key":"1205_CR53","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1158\/1078-0432.CCR-15-1191","volume":"22","author":"M Klanova","year":"2016","unstructured":"Klanova, M., Andera, L., Brazina, J., Svadlenka, J., Benesova, S., Soukup, J. et al. Targeting of BCL2 family proteins with ABT-199 and homoharringtonine reveals BCL2- and MCL1-dependent subgroups of diffuse large B-cell lymphoma. Clin. Cancer Res. 22, 1138\u20131149 (2016).","journal-title":"Clin. Cancer Res"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41416-020-01205-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-020-01205-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-020-01205-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,13]],"date-time":"2021-12-13T20:03:20Z","timestamp":1639425800000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-020-01205-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,14]]},"references-count":53,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,3,16]]}},"alternative-id":["1205"],"URL":"https:\/\/doi.org\/10.1038\/s41416-020-01205-9","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,14]]},"assertion":[{"value":"6 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 November 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 December 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Animal studies were approved by the Institutional Animal Care and Use Committee (protocol AUP-18-050) at UC Irvine (accredited by American Association for Accreditation of Laboratory Animal Care). No human subjects research was performed.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All data supporting the findings of this study are available within the article and its\u00a0\n                      \n                      , or from the corresponding author on reasonable request. All RNA-seq data files along with their associated metadata have been deposited in the GEO database under the accession code GSE159906.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was supported by: National Institutes of Health grant R01-CA158383 (to D.A.F.), R01-CA202021 (to Z.A.R.), R01-CA178509 (to R.J.S.), American Society for Hematology Bridge grant ASH-5557789 (to D.A.F.), Breast Cancer Research Fund grant BCRF-16-143 (to R.J.S.), Melanoma Research Alliance award 509524 (to Z.A.R.), UC Irvine Chao Family Comprehensive Cancer Center pilot grant from the 2018 Anti-Cancer Challenge (to D.A.F.), and by Cancer Center Support Grant P30-CA062203 to UC Irvine (PI: Van Etten). L.H. and H.C. were supported by National Institutes of Health grant T32 AI 060573. B.W. was supported by a National Institutes of Health grant T32 CA9161.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding information"}}]}}